Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20676018 | 0.92 | SMN1; SMN2 (0.85) | HTTSMN1; SMN2HPGDALDH1A1L3MBTL1 | |
| SCHEMBL4740663 | 0.87 | SMN1; SMN2 (0.76) | HTTSMN1; SMN2HPGDALDH1A1L3MBTL1 | |
| SCHEMBL1902358 | 0.86 | SMN1; SMN2 (0.76) | HTTSMN1; SMN2HPGDALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL1373954 | 0.85 | SMN1; SMN2 (0.74) | HTTSMN1; SMN2HPGDALDH1A1L3MBTL1 | |
| SCHEMBL7459479 | 0.85 | SMN1; SMN2 (1.00) | HTTSMN1; SMN2HPGDALDH1A1L3MBTL1 | |
| SCHEMBL7462638 | 0.85 | HTT (0.73) | HTTSMN1; SMN2HPGDALDH1A1L3MBTL1 | |
| SCHEMBL8293397 | 0.83 | HTT (0.71) | HTTSMN1; SMN2HPGDALDH1A1L3MBTL1 | |
| SCHEMBL7462557 | 0.82 | ALDH1A1 (0.71) | HTTSMN1; SMN2HPGDALDH1A1L3MBTL1 | |
| SCHEMBL4095420 | 0.82 | SMN1; SMN2 (0.73) | HTTSMN1; SMN2HPGDALDH1A1L3MBTL1 | |
| SCHEMBL10636415 | 0.81 | HTT (0.68) | HTTSMN1; SMN2HPGDALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | claimed |
| US-20240011009-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2024-01-11 | — | — | US | claimed |
| US-20230220589-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2023-07-13 | — | — | US | claimed |
| EP-4127157-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2022072560-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2021194908-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2021-09-30 | — | — | WO | claimed |
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20240208955-A1 | SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM | RESEARCH TRIANGLE INSTITUTE | 2024-06-27 | — | — | US | disclosed |
| EP-4304630-A1 | SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM | Research Triangle Institute (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20240011009-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2024-01-11 | — | — | US | disclosed |
| US-11788080-B2 | Modified cleavases, uses thereof and related kits | Encodia, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230257727-A1 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2023-08-17 | — | — | US | disclosed |
| EP-4127157-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-7910590-B2 | Cyclic amine bace-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION | 2009-12-17 | — | — | US | disclosed |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION | 2009-12-17 | — | — | US | disclosed |
| US-7598250-B2 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598250-B2 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| EP-1660447-B1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1180513-A1 | CYCLIC AMIDE COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208955-A1 | SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM | RXFP3, RXFP1, RXFP4 | HTT 1614/4885SMN1; SMN2 3711/4885HPGD 2062/4885 |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | BACE1, BACE2, PSEN1 | HTT 113/4885SMN1; SMN2 199/4885HPGD 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.